AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.
Pfizer Reports Updated Data from Phase III Study on Ibrance
by Zacks Equity Research
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
by Zacks Equity Research
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
by Zacks Equity Research
AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.
Foreign Stock Roundup: Statoil Buys Oil Field Stakes for $1.45B, Shell Resumes Dividend Payment
by Swarup Gupta
A selloff in tech stocks and a crucial U.S. tax legislation dominated proceedings for Europe's bourses this week.
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
by Zacks Equity Research
The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.
How Will U.S. Tax Reform Impact Pharma/Biotech Industry?
by Zacks Equity Research
After certain modifications to the original plan over the past year, the tax reform bill is expected to be voted on by the Congress this week. Let's see how this vote will impact the pharma/biotech industry.
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
by Zacks Equity Research
AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.
AstraZeneca Files for Label Expansion of Tagrisso in Japan
by Zacks Equity Research
AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.
2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17
by Zacks Equity Research
Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU
by Zacks Equity Research
This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry
by Zacks Equity Research
Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.
3 Companies Competing to Gain Lead in Ovarian Cancer Market
by Zacks Equity Research
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
by Arpita Dutt
Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.
Parkinson's Space in Focus as Acorda Stops Tozadenant Trial
by Zacks Equity Research
Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
by Zacks Equity Research
Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU
by Zacks Equity Research
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
by Zacks Equity Research
Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca
Cancer Space Update: Label Expansion for Three Major Drugs
by Zacks Equity Research
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.